McNeil Consumer Pharmaceuticals Co Sustainability Profile
McNeil Consumer Pharmaceuticals Co., a subsidiary of Johnson & Johnson, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1959, the company has established itself as a leader in over-the-counter (OTC) medications, focusing on areas such as pain relief, allergy treatment, and digestive health. With a diverse portfolio that includes well-known products like Tylenol, Motrin, and Pepcid, McNeil is recognised for its commitment to quality and consumer trust. The company has achieved significant milestones, including the development of innovative formulations that cater to various health needs. As a key contributor to the OTC market, McNeil Consumer Pharmaceuticals Co. continues to uphold its reputation for excellence, making it a trusted choice for consumers seeking effective healthcare solutions.
DitchCarbon Score
How does McNeil Consumer Pharmaceuticals Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
McNeil Consumer Pharmaceuticals Co's score of 51 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
McNeil Consumer Pharmaceuticals Co, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Kenvue Inc., which may influence its climate commitments and reporting practices. As part of its corporate family, McNeil Consumer Pharmaceuticals Co inherits climate initiatives and targets from Kenvue Inc. However, there are no documented reduction targets or significant climate pledges available for McNeil at this time. This lack of specific data suggests that the company may still be in the process of establishing its own distinct climate strategy or reporting framework. In the broader context of the industry, companies are increasingly focusing on sustainability and carbon reduction, often setting ambitious targets aligned with the Science Based Targets initiative (SBTi) and other frameworks. While McNeil Consumer Pharmaceuticals Co has not yet disclosed its specific commitments, it is likely to align with the sustainability goals set forth by its parent company, Kenvue Inc., as part of a collective effort to address climate change and reduce carbon footprints across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 73,841,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 136,832,000 | 000,000,000 | 000,000,000 | - | - |
| Scope 3 | 3,652,178,000 | 0,000,000,000 | 0,000,000,000 | - | - |
How Carbon Intensive is McNeil Consumer Pharmaceuticals Co's Industry?
How Carbon Intensive is McNeil Consumer Pharmaceuticals Co's Location?
McNeil Consumer Pharmaceuticals Co's Scope 3 Categories Breakdown
McNeil Consumer Pharmaceuticals Co's Scope 3 emissions, which decreased by 19% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Top Scope 3 Categories
McNeil Consumer Pharmaceuticals Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
McNeil Consumer Pharmaceuticals Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
